KKM Financial LLC Grows Stock Holdings in Pfizer Inc. $PFE

KKM Financial LLC grew its position in Pfizer Inc. (NYSE:PFE) by 28.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 149,996 shares of the biopharmaceutical company’s stock after buying an additional 33,601 shares during the period. KKM Financial LLC’s holdings in Pfizer were worth $3,822,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Vanguard Group Inc. lifted its position in Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after acquiring an additional 10,198,330 shares during the last quarter. Norges Bank acquired a new position in shares of Pfizer during the second quarter worth $2,270,157,000. Fisher Asset Management LLC lifted its holdings in shares of Pfizer by 1.9% during the 3rd quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after purchasing an additional 897,786 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Pfizer by 2.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after purchasing an additional 1,135,457 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Pfizer by 8.6% in the 3rd quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after purchasing an additional 3,296,415 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.0%

Shares of PFE stock opened at $26.60 on Monday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94. The stock has a market cap of $151.23 billion, a P/E ratio of 19.56 and a beta of 0.47. The stock has a 50 day moving average of $26.50 and a 200 day moving average of $25.53. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Analyst Ratings Changes

PFE has been the topic of several recent analyst reports. Barclays initiated coverage on Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price on the stock. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. HSBC reaffirmed a “buy” rating and set a $29.00 price target on shares of Pfizer in a research report on Wednesday, December 10th. Finally, Bank of America decreased their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $28.05.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.